{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T07:02:02Z","timestamp":1782025322747,"version":"3.54.5"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001807","name":"FAPESP","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tissue and Cell"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.tice.2022.101762","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T17:34:24Z","timestamp":1645551264000},"page":"101762","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["OncoTherad\u00ae (MRB-CFI-1) nano-immunotherapy reduced tumoral progression in non-muscle invasive bladder cancer through activation of Toll-like signaling pathway"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2939-3501","authenticated-orcid":false,"given":"I.B.","family":"Reis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3783-9331","authenticated-orcid":false,"given":"L.H.S.","family":"Tibo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6840-5114","authenticated-orcid":false,"given":"E.A.R.","family":"Socca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9373-6989","authenticated-orcid":false,"given":"B.R.","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Dur\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5830-8938","authenticated-orcid":false,"given":"W.J.","family":"F\u00e1varo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tice.2022.101762_bib0005","doi-asserted-by":"crossref","first-page":"17048","DOI":"10.1200\/JCO.2020.38.15_suppl.e17048","article-title":"Oncotherad immunotherapy elicits promising responses in Bacillus Calmette-Gu\u00e9rin-unresponsive non\u2013muscle invasive bladder cancer: results from phase I\/II study","volume":"38","author":"Alonso","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tice.2022.101762_bib0010","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1475-2867-11-33","article-title":"IFN-\u03b3, IL-17 and TGF-\u03b2 involvement in shaping the tumor microenvironment: the significance of modulating such cytokines in treating malignant solid tumors","volume":"11","author":"Alshaker","year":"2011","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.tice.2022.101762_bib0015","series-title":"Overview: Bladder Cancer. in: What Are the Key Statistics About Bladder Cancer? American Cancer society, Atlanta","author":"American Cancer Society","year":"2021"},{"key":"10.1016\/j.tice.2022.101762_bib0020","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder cancer incidence and mortality: a global overview and recent trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.tice.2022.101762_bib0025","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/181987","article-title":"Bladder Cancer immunotherapy: BCG and beyond","author":"Askeland","year":"2012","journal-title":"Adv. Urol."},{"key":"10.1016\/j.tice.2022.101762_bib0030","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.juro.2010.12.097","article-title":"Toll-like receptors in normal and malignant human bladders","volume":"185","author":"Ayari","year":"2011","journal-title":"J. Urol."},{"key":"10.1016\/j.tice.2022.101762_bib0035","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1442-2042.1996.tb00490.x","article-title":"Local toxicity patterns associated with intravesical bacillus Calmette-Guerin: a Southwest Oncology Group study","volume":"3","author":"Berry","year":"1996","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.tice.2022.101762_bib0040","doi-asserted-by":"crossref","DOI":"10.1088\/1742-6596\/1323\/1\/012022","article-title":"New therapeutic perspective for bladder cancer in dogs: toxicological and clinical effects of oncotherad nanostructured immunotherapy","author":"B\u00f6ckelmann","year":"2019","journal-title":"J. Phys. Conf. Ser."},{"key":"10.1016\/j.tice.2022.101762_bib0045","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/01.ju.0000073852.24341.4a","article-title":"Immune mechanisms in Bacillus calmette-Guerin immunotherapy for superficial bladder cancer","volume":"170","author":"Bohle","year":"2003","journal-title":"J. Urol."},{"key":"10.1016\/j.tice.2022.101762_bib0050","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00345-007-0229-9","article-title":"Urinary markers in screening patients with hematuria","volume":"26","author":"Chiong","year":"2008","journal-title":"World J. Urol."},{"key":"10.1016\/j.tice.2022.101762_bib0055","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.juro.2007.08.063","article-title":"Bacillus Calmette-Guerin mechanism of action: role of immunity, apoptosis, necrosis and autophagy","volume":"178","author":"DiPaola","year":"2007","journal-title":"J. Urol."},{"key":"10.1016\/j.tice.2022.101762_bib0060","doi-asserted-by":"crossref","DOI":"10.1088\/1742-6596\/1323\/1\/012018","article-title":"OncoTherad: a new nanobiological response modifier, its toxicological and anticancer activities","volume":"1323","author":"Dur\u00e1n","year":"2019","journal-title":"J. Phys. Conf. Ser."},{"key":"10.1016\/j.tice.2022.101762_bib0065","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/00000478-199812000-00001","article-title":"The World Health Organization\/International Society of Urologic Pathology consensus classification of urothelial (transitional) neoplasms of the urinary bladder","volume":"22","author":"Epistein","year":"1998","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.tice.2022.101762_bib0070","series-title":"A Method for Producing a Nanostructured Complex (cfi-1), a Protein-associated Nanostructured Complex (mrb-cfi-1) and Use. US Patent App. 16\/617,493","author":"F\u00e1varo","year":"2020"},{"key":"10.1016\/j.tice.2022.101762_bib0075","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1750-9378-7-14","article-title":"Effects of P-MAPA immunomodulator on toll-like receptors and p53: potential therapeutic strategies for infectious diseases and Cancer","volume":"7","author":"F\u00e1varo","year":"2012","journal-title":"Infect Agent Cancer."},{"key":"10.1016\/j.tice.2022.101762_bib0080","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e16000","article-title":"Single-arm phase I\/II study of the safety and efficacy of OncoTherad immunomodulator in patients BCG-refractory or relapsed non-muscle invasive bladder cancer","volume":"37","author":"F\u00e1varo","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tice.2022.101762_bib0085","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e16004","article-title":"Role of OncoTherad immunotherapy in the regulation of toll-like receptors-mediated immune system and RANK\/RANKL signaling: new therapeutic perspective for non-muscle invasive bladder cancer","volume":"37","author":"F\u00e1varo","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tice.2022.101762_bib0090","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2021.707025","article-title":"Current status of canine melanoma diagnosis and therapy","author":"Fonseca-Alves","year":"2021","journal-title":"Front. Vet. Sci."},{"key":"10.1016\/j.tice.2022.101762_bib0095","first-page":"4427","article-title":"Alterations in ubiquitin ligase Siah-2 and its corepressor N-CoR after P-MAPA immunotherapy and anti-androgen therapy: new therapeutic opportunities for non-muscle invasive bladder cancer","volume":"8","author":"Garcia","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.tice.2022.101762_bib0100","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1186\/s12885-016-2474-z","article-title":"Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: mechanism of action of P-MAPA biological response modifier","volume":"16","author":"Garcia","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.tice.2022.101762_bib0105","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1172\/JCI10501","article-title":"Salmonella typhimurium translocates flagellin across intestinal epithelia, inducing a proinflammatory response","volume":"107","author":"Gerwirtz","year":"2001","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.tice.2022.101762_bib0110","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.4049\/jimmunol.174.5.2942","article-title":"Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88","volume":"174","author":"Hasan","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.tice.2022.101762_bib0115","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.12-1-20","article-title":"Cancer statistics, trends, and multiple primary cancer analyses from the surveillance, epidemiology, and end results (SEER) Program","volume":"12","author":"Hayat","year":"2007","journal-title":"Oncologist."},{"key":"10.1016\/j.tice.2022.101762_bib0120","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/MOU.0000000000000753","article-title":"Catalog of exogenous risk factors for bladder carcinogenesis","volume":"30","author":"Jahrreiss","year":"2020","journal-title":"Curr. Opin. Urol."},{"key":"10.1016\/j.tice.2022.101762_bib0125","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"4","author":"Kamat","year":"2017","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.tice.2022.101762_bib0130","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1371\/journal.pone.0102974","article-title":"Regulation of the innate immune response by fibronectin: synergism between the III-1 and EDA domains","volume":"9","author":"Kelsh","year":"2014","journal-title":"PlosOne."},{"key":"10.1016\/j.tice.2022.101762_bib0135","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/sj.bjc.6603275","article-title":"Exploitation of the Toll like receptor system in cancer: a doubled-edged sword?","volume":"95","author":"Killeen","year":"1996","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tice.2022.101762_bib0140","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jhep.2006.05.018","article-title":"Interferon-gamma produced by interleukin-12-activated tumor infiltrating CD8+T cells directly induces apoptosis of mouse hepatocellular carcinoma","author":"Komita","year":"2006","journal-title":"J. Hepatol."},{"issue":"191","key":"10.1016\/j.tice.2022.101762_bib0145","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.juro.2013.07.102","article-title":"Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition","volume":"2014","author":"Lamm","year":"2014","journal-title":"J. Urol."},{"key":"10.1016\/j.tice.2022.101762_bib0150","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ccr.2004.08.012","article-title":"Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression","volume":"6","author":"Luo","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tice.2022.101762_bib0155","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.vaccine.2010.03.007","article-title":"IFN-gamma-Mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate Cancer","volume":"28","author":"Martini","year":"2010","journal-title":"Vaccine."},{"key":"10.1016\/j.tice.2022.101762_bib0160","first-page":"10","article-title":"Toll-like receptors","volume":"6","author":"McKeown-Longo","year":"2017","journal-title":"Adv. Wound Care (New Rochelle)"},{"key":"10.1016\/j.tice.2022.101762_bib0165","series-title":"Genetic Alterations in Urothelial Bladder Carcinoma: an Updated Review","first-page":"1205","author":"Mhawech-Fauceglia","year":"2006"},{"key":"10.1016\/j.tice.2022.101762_bib0170","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1158\/1078-0432.CCR-10-2981","article-title":"In vivo evaluation of mucoadhesive nanoparticulate Docetaxel for intravesical treatment of Non-Muscle-Invasive bladder cancer","volume":"9","author":"Mugabe","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tice.2022.101762_bib0175","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3892\/ijmm.2021.4844","article-title":"Vitamin D, zinc and glutamine: synergistic action with OncoTherad immunomodulator in interferon signaling and COVID\u201119 (Review)","volume":"47","author":"Name","year":"2021","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.tice.2022.101762_bib0180","first-page":"3565","article-title":"Superantigen-activated mononuclear cells induce apoptosis in transitional cell carcinoma","volume":"25","author":"Perabo","year":"2005","journal-title":"Anticancer Res."},{"key":"10.1016\/j.tice.2022.101762_bib0185","first-page":"86","article-title":"Distinct microenvironmental cues stimulate divergent TLR4-mediated signaling pathways in macrophages","volume":"9","author":"Piccinini","year":"2016","journal-title":"Science Sign."},{"key":"10.1016\/j.tice.2022.101762_bib0190","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/wrr.12381","article-title":"Exacerbated and prolonged inflammation impairs wound healing and increases scarring","volume":"24","author":"Qian","year":"2016","journal-title":"Wound Repair Regen."},{"key":"10.1016\/j.tice.2022.101762_bib0195","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.juro.2011.10.022","article-title":"Anti-angiogenic effects of the superantigen staphylococcal enterotoxin B and Bacillus Calmette-Gu\u00e9rin immunotherapy for nonmuscle invasive bladder cancer","volume":"2","author":"Reis","year":"2012","journal-title":"J. Urol."},{"key":"10.1016\/j.tice.2022.101762_bib0200","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S0022-5347(01)65921-4","article-title":"Localization of IL-1, IL-2, IL-4, IL-8 and TNF in superficial bladder tumors treated with intravesical bacillus Calmette-Guerin","volume":"156","author":"Sander","year":"1996","journal-title":"J. Urol."},{"key":"10.1016\/j.tice.2022.101762_bib0205","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.6_suppl.462","article-title":"Modulation of the RANK\/RANKL\/OPG system and FOXP3+ regulatory T cells in the tumor microenvironment of noninvasive bladder cancer after intravesical oncotherad immunotherapy associated with platelet-rich plasma","volume":"39","author":"Sasaki","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tice.2022.101762_bib0210","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/35074122","article-title":"IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity","volume":"410","author":"Shankaran","year":"2001","journal-title":"Nature."},{"key":"10.1016\/j.tice.2022.101762_bib0215","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3810\/pgm.2011.05.2281","article-title":"Factors affecting valrubicin response in patients with bacillus Calmette-Gu\u00e9rin-refractory bladder carcinoma in situ","volume":"123","author":"Steinberg","year":"2011","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.tice.2022.101762_bib0220","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4236\/jct.2015.62014","article-title":"Molecular assessment of non-muscle invasive and muscle invasive bladder tumors: mapping of putative urothelial stem cells and toll-like receptors (TLR) signaling","volume":"6","author":"Stopglia","year":"2015","journal-title":"J. Cancer Therapy."},{"key":"10.1016\/j.tice.2022.101762_bib0225","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.smim.2003.10.003","article-title":"TLR signaling pathways","volume":"16","author":"Takeda","year":"2004","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.tice.2022.101762_bib0230","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.7150\/ijbs.4694","article-title":"Interferon-gamma-induced nitric oxide inhibits the proliferation of murine renal cell carcinoma cells","volume":"8","author":"Tate","year":"2012","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.tice.2022.101762_bib0235","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity."},{"key":"10.1016\/j.tice.2022.101762_bib0240","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40273-014-0194-2","article-title":"The health economics of Bladder Cancer: an updated review of the published literature","volume":"32","author":"Yeung","year":"2014","journal-title":"Pharmacoeconomics."},{"key":"10.1016\/j.tice.2022.101762_bib0245","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.juro.2006.09.074","article-title":"Immunotherapy for orthotopic murine bladder cancer using bacillus Calmette-Guerin recombinant protein Mpt-64","volume":"177","author":"Yu D.S","year":"2007","journal-title":"J. Urol."},{"key":"10.1016\/j.tice.2022.101762_bib0250","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0008-6363(02)00512-6","article-title":"TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS","volume":"56","author":"Zeuke","year":"2002","journal-title":"Cardiovasc. Resear."},{"key":"10.1016\/j.tice.2022.101762_bib0255","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jclinpath-2011-200312","article-title":"Receptor activator for nuclear factor \u03baB expression predicts poor prognosis in breast cancer patients with bone metastasis but not in patients with visceral metastasis","volume":"65","author":"Zhang","year":"2012","journal-title":"J. Clin. Pathol."}],"container-title":["Tissue and Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040816622000349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040816622000349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T20:23:51Z","timestamp":1758572631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040816622000349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":51,"alternative-id":["S0040816622000349"],"URL":"https:\/\/doi.org\/10.1016\/j.tice.2022.101762","relation":{},"ISSN":["0040-8166"],"issn-type":[{"value":"0040-8166","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"OncoTherad\u00ae (MRB-CFI-1) nano-immunotherapy reduced tumoral progression in non-muscle invasive bladder cancer through activation of Toll-like signaling pathway","name":"articletitle","label":"Article Title"},{"value":"Tissue and Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tice.2022.101762","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101762"}}